Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis.

variants irrespective of the phenotype, and therefore recommend that VPA is contraindicated in this group. However, there was limited evidence of toxicity to support a similar recommendation in other genotypes of mitochondrial diseases.